Terms: = Liver cancer AND AXIN1, LA16c-314G4_3, 8312, ENSG00000103126, O15169, AXIN, MGC52315 AND Treatment
29219 results:
1. A multi-parametric prognostic model based on clinicopathologic features: vessels encapsulating tumor clusters and hepatic plates predict overall survival in hepatocellular carcinoma patients.
Xiong SP; Wang CH; Zhang MF; Yang X; Yun JP; Liu LL
J Transl Med; 2024 May; 22(1):472. PubMed ID: 38762511
[TBL] [Abstract] [Full Text] [Related]
2. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases.
Wang X; Yang Y
Medicine (Baltimore); 2024 May; 103(20):e38174. PubMed ID: 38758900
[TBL] [Abstract] [Full Text] [Related]
3. Epstein
Peng L; Peng X; Duan S; Zhang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 49(2):319-330. PubMed ID: 38755729
[TBL] [Abstract] [Full Text] [Related]
4. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
[TBL] [Abstract] [Full Text] [Related]
5. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract] [Full Text] [Related]
6. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
7. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
[TBL] [Abstract] [Full Text] [Related]
8. Dynamic evaluation of liver fibrosis to assess hepatocellular carcinoma risk in patients with chronic hepatitis B receiving nucleoside analogs treatment.
Luo J; Yuan M; Li S; Chen L; Zhou M; Li H; Bai X; Zhang Z; Zeng W; Sun X; Zhang Q; Chen Y; Zhou L
Rev Inst Med Trop Sao Paulo; 2024; 66():e27. PubMed ID: 38747848
[TBL] [Abstract] [Full Text] [Related]
9. Rice bran arabinoxylan compound as a natural product for cancer treatment - an evidence-based assessment of the effects and mechanisms.
Ooi SL; Micalos PS; Kim J; Pak SC
Pharm Biol; 2024 Dec; 62(1):367-393. PubMed ID: 38745507
[TBL] [Abstract] [Full Text] [Related]
10. [Aprospective study of detection and clinical significance of bone marrow tumor cells in small cell lung cancer].
Wang Y; Lu BH; Gao Y; Liu YX; Hu MM; Che NY; Lin HF; Li HX; Zhang HM; Zhang TM
Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):419-427. PubMed ID: 38742355
[No Abstract] [Full Text] [Related]
11. Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma.
Kasuga R; Taniki N; Chu PS; Tamura M; Tabuchi T; Yamaguchi A; Hayatsu S; Koizumi J; Ojiro K; Hoshi H; Kaneko F; Morikawa R; Noguchi F; Yamataka K; Usui S; Ebinuma H; Itano O; Hasegawa Y; Abe Y; Kitago M; Inoue M; Nakatsuka S; Jinzaki M; Kitagawa Y; Kanai T; Nakamoto N
Sci Rep; 2024 May; 14(1):10896. PubMed ID: 38740983
[TBL] [Abstract] [Full Text] [Related]
12. Blood Pressure, Readmission, and Mortality Among Patients Hospitalized With Acute Kidney Injury.
Griffin BR; Vaughan-Sarrazin M; Shi Q; Ten Eyck P; Reisinger HS; Kennelty K; Good MK; Swee ML; Yamada M; Lund BC; Jalal DI
JAMA Netw Open; 2024 May; 7(5):e2410824. PubMed ID: 38739389
[TBL] [Abstract] [Full Text] [Related]
13. Seven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis.
Liu K; Li Q; Lu X; Fan X; Yang Y; Xie W; Kang J; Sun S; Zhao J
Pharm Biol; 2024 Dec; 62(1):404-422. PubMed ID: 38739082
[TBL] [Abstract] [Full Text] [Related]
14. [Curative effect of percutaneous microwave ablation therapy on hepatocellular carcinoma survival: a 15-year real-world study].
Luo YC; Lang ML; Cai WJ; Han ZY; Liu FY; Cheng ZG; Yu XL; Dou JP; Li X; Tan SL; Dong XJ; Liang P; Yu J
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):332-339. PubMed ID: 38733188
[No Abstract] [Full Text] [Related]
15. Clinical features of patients with carcinoma soft tissue metastases as surgical indications: a retrospective cohort study.
Morinaga S; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Taniguchi Y; Asano Y; Nojima T; Tsuchiya H
BMC Cancer; 2024 May; 24(1):577. PubMed ID: 38730358
[TBL] [Abstract] [Full Text] [Related]
16. Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations.
Rached L; Laparra A; Sakkal M; Danlos FX; Barlesi F; Carbonnel F; De Martin E; Ducreux M; Even C; Le Pavec J; Michot JM; M Ribeiro J; Scotte F; Ponce Aix S; Lambotte O; Baldini C; Champiat S
Cancer Treat Rev; 2024 Jun; 127():102751. PubMed ID: 38729086
[TBL] [Abstract] [Full Text] [Related]
17. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
[TBL] [Abstract] [Full Text] [Related]
18. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S; Xiong A; Yu J; Wang X; Han B; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
Cancer Immunol Immunother; 2024 May; 73(7):124. PubMed ID: 38727837
[TBL] [Abstract] [Full Text] [Related]
19. Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.
Shindo T; Hashimoto K; Fujino K; Takahashi A; Hotta H; Maeda T; Kunishima Y; Fukuta F; Ito N; Wanifuchi A; Kato R; Okada M; Matsukawa M; Horita H; Takayanagi A; Kobayashi K; Tanaka T; Masumori N
World J Urol; 2024 May; 42(1):307. PubMed ID: 38722418
[TBL] [Abstract] [Full Text] [Related]
20. IL-2RG as a possible immunotherapeutic target in CRC predicting poor prognosis and regulated by miR-7-5p and miR-26b-5p.
Gharib E; Rejali L; Piroozkhah M; Zonoobi E; Nasrabadi PN; Arabsorkhi Z; Baghdar K; Shams E; Sadeghi A; Kuppen PJK; Salehi Z; Nazemalhosseini-Mojarad E
J Transl Med; 2024 May; 22(1):439. PubMed ID: 38720389
[TBL] [Abstract] [Full Text] [Related]
[Next]